Sensus Healthcare Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sensus Healthcare in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Sensus Healthcare stock.
View analyst ratings for Sensus Healthcare or view top-rated stocks.

Wall Street analysts have given Sensus Healthcare a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sensus Healthcare wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Sensus Healthcare is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Sensus Healthcare.

Sensus Healthcare, Inc. (NASDAQ:SRTS) posted its quarterly earnings results on Thursday, August, 5th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.03. The business had revenue of $5.42 million for the quarter, compared to analyst estimates of $4.07 million. Sensus Healthcare had a negative net margin of 13.60% and a negative trailing twelve-month return on equity of 10.02%.
View Sensus Healthcare's earnings history.

Sensus Healthcare's stock was trading at $3.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SRTS shares have increased by 8.0% and is now trading at $3.51.
View which stocks have been most impacted by COVID-19.

4 brokers have issued 12-month price targets for Sensus Healthcare's stock. Their forecasts range from $6.00 to $7.00. On average, they anticipate Sensus Healthcare's share price to reach $6.33 in the next year. This suggests a possible upside of 80.4% from the stock's current price.
View analysts' price targets for Sensus Healthcare or view top-rated stocks among Wall Street analysts.

Some companies that are related to Sensus Healthcare include DarioHealth (DRIO), TELA Bio (TELA), Titan Medical (TMDI), Neuronetics (STIM), T2 Biosystems (TTOO), Nemaura Medical (NMRD), Repro Med Systems (KRMD), Liquidia (LQDA), PolyPid (PYPD), BrainsWay (BWAY), Venus Concept (VERO), Repro-Med Systems (REPR), AIT Therapeutics (AITB), Lyra Therapeutics (LYRA) and Pro-Dex (PDEX).
View all of SRTS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sensus Healthcare investors own include Ring Energy (REI), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Nabriva Therapeutics (NBRV), Sangamo Therapeutics (SGMO), Viking Therapeutics (VKTX), Vaxart (VXRT), Amarin (AMRN), Palatin Technologies (PTN) and QUALCOMM (QCOM).

(SRTS) raised $20 million in an IPO on Wednesday, March 30th 2016. The company issued 1,800,000 shares at a price of $10.00-$12.00 per share. Joseph Gunnar and Feltl and Company served as the underwriters for the IPO and Neidiger, Tucker, Bruner was co-manager.

Sensus Healthcare trades on the NASDAQ under the ticker symbol "SRTS."

Sensus Healthcare's stock is owned by many different institutional and retail investors. Top institutional shareholders include Invenomic Capital Management LP (1.62%), Financial Engines Advisors L.L.C. (0.49%), Geode Capital Management LLC (0.42%), Citadel Advisors LLC (0.21%), Morgan Stanley (0.06%) and Morgan Stanley (0.06%).
View institutional ownership trends for Sensus Healthcare.

SRTS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Invenomic Capital Management LP, and Citadel Advisors LLC.
View insider buying and selling activity for Sensus Healthcare or view top insider-selling stocks.

SRTS stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, and Financial Engines Advisors L.L.C..
View insider buying and selling activity for Sensus Healthcare or or view top insider-buying stocks.

Shares of SRTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SRTS stock can currently be purchased for approximately $3.51.

Sensus Healthcare has a market capitalization of $58.34 million and generates $9.58 million in revenue each year. The company earns $-6,840,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis.

Sensus Healthcare employs 42 workers across the globe.

The official website for Sensus Healthcare is www.sensushealthcare.com.

Sensus Healthcare is headquartered at 851 BROKEN SOUND PARKWAY NW SUITE 215, BOCA RATON FL, 33487.

Sensus Healthcare's mailing address is 851 BROKEN SOUND PARKWAY NW SUITE 215, BOCA RATON FL, 33487. The company can be reached via phone at (561) 922-5808 or via email at [email protected]